• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Deal Volume Takes Hit But Value of Healthcare Transactions Climbs

Article

Healthcare firms completed fewer deals in the second quarter of this year compared with the prior quarter, but the overall value of the transactions surged on the heels of a number of blockbuster tie-ups.

Read the full story: http://bit.ly/NOEXI2

Source: ModernHealthcare.com

In total, the healthcare industry completed 321 deals in the second quarter, a 20% decrease compared with the 401 deals recorded in the first three months of the year. But acquirers put more money on the table, with the value of disclosed deals jumping 214.7% to reach $50.6 billion compared with $16.1 billion in the first quarter, according to Healthcare M&A Watch, Modern Healthcare's new quarterly report on healthcare merger and acquisition activity.

Related Videos
4 experts in this video
4 experts in this video
Rakendu Rajendran, MBBS
Vivek Bhalla, MD, Stanford University School of Medicine
Dr Carla Nester
Rayan Salih, MD, Northeast Georgia Health System
Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Mount Sinai Fuster Heart Hospital
AJMC interview with Ali Shan Hafeez and Dr Abdul Rafae Faisal | Background image credit: ipopba - stock.adobe.com
Related Content
Hospital staff stocktaking in pharmacy | Image credit: Jacob Lund - stock.adobe.com

How Hospital Pharmacies Are Tackling Rising Drug Costs

August 6th 2025
Article

A new report from Bluesight reveals how automation and analytics are helping hospital pharmacy teams cut spending, manage shortages, and streamline procurement.

Read More

AJMC podcast banner

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

August 5th 2025
Podcast

Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.

Listen

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025
Article

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Read More

The Center for Biosimilars podcast banner

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

July 29th 2025
Podcast

Listen

RSV, COVID, Flu vaccines. | Image credit: angellodeco - stock.adobe.com

RFK Jr Axes $500 Million in Funding for mRNA Vaccine Development

August 6th 2025
Article

Robert F. Kennedy Jr halted 22 mRNA vaccine initiatives, drawing criticism from health experts over pandemic preparedness concerns.

Read More

myasthenia gravis | Image Credit: © Maggie-sora.chatgpt.com

Unique Psychological Burden of Fear of Progression Seen in MG

August 6th 2025
Article

Fear of progression is common among patients living with chronic diseases, but the degree to which it interferes with patient outcomes, including treatment adherence, deserves further investigation, study authors note.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.